Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ad-sig-hMUC-1/ecdCD40L Vector Vaccine for Immunotherapy of Epithelial Cancers

Trial Profile

Ad-sig-hMUC-1/ecdCD40L Vector Vaccine for Immunotherapy of Epithelial Cancers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CD40 ligand MUC1 loaded dendritic cell vaccine (Primary)
  • Indications Adenocarcinoma; Breast cancer; Colon cancer; Lung cancer; Ovarian cancer; Prostate cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 05 Jun 2018 Results (n=18) assessing dose-escalation cohort in a phase 1 study of Ad-sig-hMUC-1/ecdCD40L vector vaccine, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 New source identified and integrated (ClinicalTrials.gov NCT02140996).
    • 18 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top